|
TWST: Would you give us a brief historical sketch of the company and a
picture of the things you're doing at the present time?
Mr. Yarbrough: The company was founded about 19 years ago, and
originally began as an external fixation company in Verona, Italy. So
what was once a company that got the majority of its revenues
internationally, now gets two-thirds of its revenues from the US. That's
one way we have expanded over the years. Though we started mainly as an
external fixation company and that is still certainly a good part of our
total revenues, we now get roughly one-third of our revenues from spinal
stimulation. And we also have a long bone stimulation device.
Additionally, about 20% to 25% of our total revenues come from an
acquisition that the company made about two and a half years ago called
BREG. About 55% of their revenues come from functional bracing, such as
what you wear if you hurt your knee. The balance of their revenues come
from pain management, consisting of infusion pumps, and also from cold
therapy products. So you can see that there has been a diversification
into different areas. In addition to the trauma area, which was the
external fixation, we now have the bracing and pain management products,
we have the spinal stimulation, and we also have a presence in the
vascular area, with a deep vein thrombosis product that we call our A-V
Impulse system. As I said, this is a product that helps prevent deep
vein thrombosis post surgically. Finally, we have a presence in the
reconstuction market through a portfolio of what I would call niche
type products. They're popular products that are used in very specific
situations, so the total market for them is fairly small. For example, a
couple of them are used for correcting bone deformities, like bowed legs
in children.
Tickers included in this excerpt: OFIX
For more information call (212) 952 7433. The
Wall Street Transcript does not endorse any of the comments made by interviewees, and does
not make stock recommendations.
|
|
